UB Paderborn / Katalog / Suche / in CDI

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism

Movement disorders, 2008-10, Vol.23 (13), p.1860-1866

2008

Link zum Volltext

Verfügbarkeit prüfen

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

Alzheimer's & dementia : translational research & clinical interventions, 2017-09, Vol.3 (3), p.339-347

2017

Link zum Volltext

Verfügbarkeit prüfen

Minor Alteration of Microtubule Dynamics Causes Loss of Tension across Kinetochore Pairs and Activates the Spindle Checkpoint

The Journal of biological chemistry, 2002-05, Vol.277 (19), p.17200-17208

2002

Link zum Volltext

Verfügbarkeit prüfen

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

Journal of clinical psychopharmacology, 2008-12, Vol.28 (6), p.631-637

2008

Link zum Volltext

Verfügbarkeit prüfen

Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth

Clinical cancer research, 2004-08, Vol.10 (15), p.5187-5201

2004

Link zum Volltext

Verfügbarkeit prüfen

Top Priorities for Cerebroprotective Studies-A Paradigm Shift: Report From STAIR XI

Stroke (1970), 2021-09, Vol.52 (9), p.3063-3071

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study

Clinical neuropharmacology, 2013, Vol.36 (1), p.14-23

2013

Link zum Volltext

Verfügbarkeit prüfen

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study

Alzheimer's & dementia : translational research & clinical interventions, 2017-09, Vol.3 (3), p.393-401

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

Clinical neuropharmacology, 2013, Vol.36 (1), p.8-13

2013

Link zum Volltext

Verfügbarkeit prüfen

Harmonizing assessments for Alzheimer's disease clinical trials: A sandwich may be a rice ball or a smörgås

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S170-S170

Landen, Jaren W

2010

Link zum Volltext

Verfügbarkeit prüfen

Burden of illness in fibromyalgia patients with comorbid depression

Clinical and experimental rheumatology, 2016-03, Vol.34 (2 Suppl 96), p.S106

2016

Link zum Volltext

Verfügbarkeit prüfen

Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma

Cancer research (Chicago, Ill.), 2002-07, Vol.62 (14), p.4109

2002

Link zum Volltext

Verfügbarkeit prüfen

Enhancing global reliability of the ADAS-cog and MMSE: part 1-the harmonization/standardization project of word lists and phrases

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S586-S586

2010

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder

Journal of pharmacokinetics and pharmacodynamics, 2009-02, Vol.36 (1), p.63-80

2009

Link zum Volltext

Verfügbarkeit prüfen

Safety and Pharmacokinetics Following a Single Infusion of the Anti-amyloid Monoclonal Antibody Ponezumab (pf-04360365) in Patients With Mild-to-moderate Alzheimer's Disease: Final Results

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.e57-e57

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety and pharmacokinetics of the anti-amyloid monoclonal antibody PF-04360365 following a single infusion in patients with mild-to-moderate Alzheimer's disease: Preliminary results

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P157-P157

2009

Link zum Volltext

Verfügbarkeit prüfen

Safety and pharmacokinetics following a single 10-minute intravenous infusion of the anti-amyloid mAb ponezumab (PF-04360365) in patients with mild to moderate Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S585-S585

2010

Link zum Volltext

Verfügbarkeit prüfen

The prevalence of brain microhemorrhages and infarcts in a cohort of patients with mild-to-moderate Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S424-S424

2010

Link zum Volltext

Verfügbarkeit prüfen

Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P253-P253

2009

Link zum Volltext

Verfügbarkeit prüfen

IP/MS analysis of human CSF Aβ following a single dose of the C-terminal anti-Aβ antibody ponezumab (PF-04360365) to Alzheimer patients

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S311-S311

2010

Link zum Volltext

Verfügbarkeit prüfen

Acute Stroke Imaging Research Roadmap IV: Imaging Selection and Outcomes in Acute Stroke Clinical Trials and Practice

Stroke (1970), 2021-08, Vol.52 (8), p.2723-2733

2021

Link zum Volltext

Verfügbarkeit prüfen

How to Establish the Outer Limits of Reperfusion Therapy

Stroke (1970), 2021-10, Vol.52 (10), p.3399-3403

2021

Link zum Volltext

Verfügbarkeit prüfen

F5‐01‐05: Harmonizing assessments for Alzheimer's disease clinical trials: A sandwich may be a rice ball or a smörgås

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_6), p.S170-S170

Landen, Jaren W.

2010

Link zum Volltext

Verfügbarkeit prüfen

Sustained Activation of p34 cdc2 Is Required for Noscapine-induced Apoptosis

The Journal of biological chemistry, 2001-12, Vol.276 (50), p.46697-46700

2001

Link zum Volltext

Verfügbarkeit prüfen

Reply to Comments by Dr Hashimoto

Journal of clinical psychopharmacology, 2009-08, Vol.29 (4), p.412

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

Minor Alteration of Microtubule Dynamics Causes Loss of Tension across Kinetochore Pairs and Activates the Spindle Checkpoint

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth

Top Priorities for Cerebroprotective Studies-A Paradigm Shift: Report From STAIR XI

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

Harmonizing assessments for Alzheimer's disease clinical trials: A sandwich may be a rice ball or a smörgås

Burden of illness in fibromyalgia patients with comorbid depression

Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma

Enhancing global reliability of the ADAS-cog and MMSE: part 1-the harmonization/standardization project of word lists and phrases

Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder

Safety and Pharmacokinetics Following a Single Infusion of the Anti-amyloid Monoclonal Antibody Ponezumab (pf-04360365) in Patients With Mild-to-moderate Alzheimer's Disease: Final Results

Safety and pharmacokinetics of the anti-amyloid monoclonal antibody PF-04360365 following a single infusion in patients with mild-to-moderate Alzheimer's disease: Preliminary results

Safety and pharmacokinetics following a single 10-minute intravenous infusion of the anti-amyloid mAb ponezumab (PF-04360365) in patients with mild to moderate Alzheimer's disease

The prevalence of brain microhemorrhages and infarcts in a cohort of patients with mild-to-moderate Alzheimer's disease

Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease

IP/MS analysis of human CSF Aβ following a single dose of the C-terminal anti-Aβ antibody ponezumab (PF-04360365) to Alzheimer patients

Acute Stroke Imaging Research Roadmap IV: Imaging Selection and Outcomes in Acute Stroke Clinical Trials and Practice

How to Establish the Outer Limits of Reperfusion Therapy

F5‐01‐05: Harmonizing assessments for Alzheimer's disease clinical trials: A sandwich may be a rice ball or a smörgås

Sustained Activation of p34 cdc2 Is Required for Noscapine-induced Apoptosis

Reply to Comments by Dr Hashimoto

Suchergebnisse filtern